

Contents

List of Contributors XVII

Foreword XXI

| | | |
|----------|--|-----------|
| 1 | Introduction to the Book | 1 |
| | <i>Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder</i> | |
| | Reference | 8 |
| 2 | Global Epidemiological Developments | 11 |
| | <i>Stephan Luther and Peter Schmitz</i> | |
| 2.1 | Introduction | 11 |
| 2.2 | Model of Epidemiological Transition | 12 |
| 2.3 | Global Burden of Diseases | 15 |
| 2.3.1 | Trends in the Distribution of Disease Burden | 16 |
| 2.4 | Infectious Diseases | 20 |
| 2.4.1 | (Re-)emerging Infectious Diseases | 23 |
| 2.4.2 | Neglected Tropical Diseases | 26 |
| 2.5 | Noncommunicable Diseases | 29 |
| 2.6 | Antimicrobial Resistance | 32 |
| 2.7 | Dynamics | 35 |
| | References | 38 |
| 3 | The Value of Pharmaceutical Innovation: Concepts and Assessment | 45 |
| | <i>Sam Salek and Paul Kamudoni</i> | |
| 3.1 | Introduction | 45 |
| 3.2 | Concepts and Definitions of Value | 46 |
| 3.3 | Stakeholder's Perspectives on Value | 47 |
| 3.3.1 | Drug Regulatory Agencies | 47 |
| 3.3.2 | Health Technology Assessment | 47 |
| 3.3.3 | Patients | 49 |
| 3.3.4 | Prescribers/Clinicians | 49 |
| 3.4 | Recent Developments Influencing the Definition and Assessment of Value | 50 |

| | | |
|----------|--|------------|
| 3.5 | Recommendations: Implications for R&D | 51 |
| 3.6 | Discussion | 52 |
| 3.7 | Conclusion | 56 |
| | References | 57 |
| 4 | A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities | 61 |
| | <i>Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder</i> | |
| 4.1 | Introduction | 61 |
| 4.2 | The Historical Perspective | 62 |
| 4.3 | The R&D Phase Model | 63 |
| 4.4 | The Low R&D Success Rates | 63 |
| 4.5 | The Long R&D Time Intervals | 67 |
| 4.6 | The High Cost of Pharmaceutical R&D | 71 |
| 4.7 | The Reduced R&D Efficiency | 73 |
| 4.8 | Can an Increase in R&D Value Compensate the Reduced R&D Efficiency? | 76 |
| | References | 78 |
| 5 | Financing Pharmaceutical Innovation | 81 |
| | <i>Sviataslau Sivagrakau</i> | |
| 5.1 | Introduction | 81 |
| 5.2 | Measuring Innovation: Categories of New Drugs | 84 |
| 5.3 | Productivity of Pharmaceutical Industry throughout Time | 86 |
| 5.4 | Measuring the Cost of Developing New Medicines | 87 |
| 5.5 | Funding Drug Development: a Global Endeavor | 91 |
| 5.6 | Public and Private Funds: Complementary Finance for Drug Development | 95 |
| 5.7 | How Commercial Drug Development Projects Are Financed Today: Big Firms, Small Firms, and Their Cooperation | 97 |
| 5.8 | Public Health Economics and Financing Pharmaceutical Innovation | 99 |
| 5.9 | Conclusion | 101 |
| | Acknowledgment | 102 |
| | References | 102 |
| 6 | Challenges and Options for Drug Discovery | 107 |
| | <i>Werner Kramer</i> | |
| 6.1 | Introduction | 107 |
| 6.2 | Paradigm Shifts of R&D Organizations | 108 |
| 6.3 | Productivity of Drug Discovery | 109 |
| 6.4 | Is There an Innovation Gap in Biomedical Research? | 111 |
| 6.4.1 | To Go for First in Class or Best in Class | 112 |
| 6.4.2 | How We Define Medical Innovation? | 112 |

| | |
|----------|--|
| 6.5 | Why Did Drug Candidates Fail? 113 |
| 6.5.1 | Why Is the Dropout Rate So High in Early Clinical Development? 115 |
| 6.5.1.1 | Drug Behavior <i>In Vivo</i> : Role of Transport Proteins 115 |
| 6.5.1.2 | Hypes and Lack of Scientific Thoroughness 116 |
| 6.6 | Implications from the "Lessons Learnt" for Future Drug Discovery Research 123 |
| 6.6.1 | Organization of Drug Discovery and Development 123 |
| 6.6.2 | Elucidation of the Physiological Validity of a Target for the Human Disease 125 |
| 6.6.2.1 | Extensive Inquiry of (All) Published Data of a Target or Pathway 125 |
| 6.6.2.2 | Integrative Knowledge Management 127 |
| 6.6.2.3 | Demonstration of the Involvement of a Target in Human Disease 128 |
| 6.6.2.4 | A Stringent and Comprehensive Test Sequence 132 |
| 6.6.2.5 | Translational Clinical Trials 135 |
| | Acknowledgment 136 |
| | References 136 |
| 7 | Translational Medicine: Enabling the Proof of Concepts 141 <i>Gezim Lahu and John Darbyshire</i> |
| 7.1 | Introduction 141 |
| 7.2 | Translational Medicine and Its Role/Value in Early Development 143 |
| 7.3 | Knowledge Generation 144 |
| 7.4 | Types of Data, Experiments, and Tools Needed to Move from Basic Research to Early Clinical Development 144 |
| 7.4.1 | Dose Selection 145 |
| 7.4.2 | Animal Models 146 |
| 7.4.3 | Fraction of NOAEL and Efficacious Dose 149 |
| 7.4.4 | Allometric Scaling and PBPK 150 |
| 7.4.5 | Physiologically Based Pharmacokinetic Models PBPK 151 |
| 7.4.6 | Pharmacokinetic and Pharmacodynamic Modeling 151 |
| 7.5 | FIM (Dose Escalation and MTD) 153 |
| 7.6 | Proof of Concept (PoC) 154 |
| | Summary 156 |
| | References 157 |
| 8 | Preclinical Safety and Risk Assessment 161 <i>Paul Germann and Rob Caldwell</i> |
| 8.1 | Introduction 161 |
| 8.2 | Test Systems 161 |
| 8.2.1 | <i>In Silico</i> Analysis 161 |
| 8.2.2 | <i>In Vitro</i> Experiments 162 |

| | | |
|-------|--|-----|
| 8.3 | Case Study: hERG Assay | 163 |
| 8.3.1 | <i>In Vivo</i> Experiments | 164 |
| 8.4 | The Preclinical "Package" during the Development of an NME | 165 |
| 8.5 | Factors Influencing the Preclinical Data Set | 166 |
| 8.5.1 | Timing and Costs | 167 |
| 8.5.2 | Intended Clinical Application Route | 167 |
| 8.5.3 | Treatment Duration and Treatment Frequency | 167 |
| 8.5.4 | Clinical Indication | 167 |
| 8.5.5 | Ongoing Changes of the Regulatory Landscape | 168 |
| 8.5.6 | New Drug Formats | 168 |
| 8.6 | Translation into Humans: The "Therapeutic Window" | 169 |
| 8.7 | Influence of Intended Therapeutic Use on the Risk Assessment (RA) | 169 |
| 8.8 | Deep Dive Case Study: Safety Assessment of Biological Drug Formats | 170 |
| 8.9 | NBE Case Study 1 | 175 |
| 8.10 | NBE Case Study 2 | 175 |
| 8.11 | Carcinogenicity Risk Assessment for Marketed Drugs | 176 |
| 8.12 | Treatment Duration | 178 |
| 8.13 | Conclusion – the "Art" of Preclinical Safety: Summarizing the Concept of Hazard Identification and Description, Risk Assessment, and Risk Management | 179 |
| | Acknowledgment | 179 |
| | Disclosures | 180 |
| | References | 180 |
| 9 | Developing Commercial Solutions for Therapeutic Proteins | 183 |
| | <i>Galina Hesse</i> | |
| 9.1 | Introduction | 183 |
| 9.2 | Developing Commercial Solutions for Therapeutic Proteins | 184 |
| 9.2.1 | Defining a Target Product Profile | 184 |
| 9.2.2 | Developing Formulations for Therapeutic Proteins | 186 |
| 9.2.3 | Testing Formulations for Therapeutic Proteins | 188 |
| 9.2.4 | Development of Primary Containers | 188 |
| 9.2.5 | Development of Application Systems | 190 |
| 9.3 | Quality by Design | 192 |
| 9.4 | Examples for Innovations in Manufacture of Sterile Pharmaceutical Products | 194 |
| 9.5 | Summary | 197 |
| | List of FDA/ICH Guidances Referenced | 198 |
| | Disclaimer | 199 |
| | References | 199 |

| | | |
|-----------|--|------------|
| 10 | The Evolution of Clinical Development: From Technical Success to Clinical Value Creation | 203 |
| | <i>Markus Hinder and Alexander Schuhmacher</i> | |
| 10.1 | Introduction | 203 |
| 10.2 | CD: Changes and Challenges | 204 |
| 10.2.1 | Clinical Endpoints: From Symptom-Oriented Endpoints to Hard and Predefined Endpoints | 204 |
| 10.2.2 | Determination and Quantification of Risks | 205 |
| 10.2.3 | Assessment of Medical Progress in Context of Available Therapeutic Options | 206 |
| 10.2.3.1 | EbM | 206 |
| 10.2.3.2 | Health Economics, Pharmacoeconomics, and the Fourth Hurdle | 207 |
| 10.2.3.3 | Results of These Changes and Challenges | 208 |
| 10.3 | Technical Success and Clinical Value Creation in CD in the Future | 208 |
| 10.3.1 | Established and Novel Approaches to Determine the Dose–Exposure–Response Relationship | 210 |
| 10.3.2 | Comparators | 212 |
| 10.3.3 | Patient Stratification to Increase Treatment Response and Benefit and Reduce Risk | 212 |
| 10.3.4 | New Operational Tools to Succeed in Trials with Increased Complexity, Special Populations, or Large Size | 213 |
| 10.3.5 | Collaboration and Outsourcing as Tools to Work in Networks | 214 |
| 10.3.6 | Collaboration across Sectors and Industries to Boost the Next Wave of Innovation | 215 |
| | Disclaimer | 218 |
| | References | 218 |
| 11 | Translational Development | 225 |
| | <i>Nigel McCracken</i> | |
| 11.1 | Introduction | 225 |
| 11.1.1 | Legacy | 226 |
| 11.2 | Translational Development | 227 |
| 11.2.1 | TP | 228 |
| 11.2.2 | Translational Toolkit | 229 |
| 11.3 | Dose Optimization | 230 |
| 11.3.1 | Physicochemical Properties | 231 |
| 11.3.2 | Target Affinity and Selectivity | 231 |
| 11.3.3 | Clearance | 231 |
| 11.3.4 | Prediction of Human Dose | 232 |
| 11.4 | Pharmacogenomics | 233 |
| 11.4.1 | Patient Segmentation | 233 |
| 11.4.2 | Disease Segmentation | 234 |
| 11.4.3 | Utility | 237 |

| | | |
|-----------|--|------------|
| 11.5 | Biomarker Development | 238 |
| 11.5.1 | Biomarker Activities | 239 |
| 11.5.2 | Assessing the Opportunity | 239 |
| 11.6 | Systems Pharmacology | 240 |
| 11.7 | Rational Drug Development | 241 |
| 11.8 | Concluding Remarks | 242 |
| | References | 242 |
| 12 | Forty Years of Innovation in Biopharmaceuticals – Will the Next 40 Years Be as Revolutionary? | 245 |
| | <i>Mathias Schmidt, Sanjay Patel, Petter Veiby, Qiang Liu, and Michael Buckley</i> | |
| 12.1 | Introduction | 245 |
| 12.1.1 | The Value Proposition of Biologics | 246 |
| 12.1.1.1 | The Patient Perspective | 246 |
| 12.1.1.2 | The Pharmaceutical Industry's Perspective | 248 |
| 12.1.2 | Biosimilars: A Blessing or a Threat to Innovation? | 250 |
| 12.1.3 | Further Innovation in Biologics – Incremental or Revolutionary? | 252 |
| 12.2 | The Evolution of Biologics Manufacturing | 252 |
| 12.2.1 | Introduction | 252 |
| 12.2.2 | CHO Cells: The Industry Workhorse | 253 |
| 12.2.3 | Protein Production Strategies | 253 |
| 12.2.4 | The Impact of Increasing Titrers on Manufacturing Facilities | 255 |
| 12.2.5 | Protein Purification Platforms | 256 |
| 12.2.6 | Conclusion: What Will the Next 40 Years of Innovation Bring? | 258 |
| 12.3 | The Evolution of Alternative Scaffolds | 259 |
| 12.3.1 | Novel Small Protein Scaffolds | 260 |
| 12.3.2 | Single-Chain Fragment Variables and Diabodies | 260 |
| 12.3.3 | Single-Domain Antibodies | 261 |
| 12.3.4 | Nonantibody Scaffolds | 261 |
| 12.3.5 | Bispecific Single-Chain Fragment Variables and Diabodies | 263 |
| 12.3.6 | Other Bispecific Antibody Formats | 264 |
| 12.4 | Antibody-Drug Conjugates | 265 |
| 12.5 | The Next Wave of Biologics | 270 |
| 12.5.1 | Orally Available Biologics | 271 |
| 12.5.2 | Biologics That Enter the Cytoplasm | 271 |
| 12.5.3 | Biologics That Pass the Blood–Brain Barrier | 272 |
| 12.5.4 | Translational Medicine as Driver of Innovation | 272 |
| | Disclaimer | 273 |
| | References | 273 |
| 13 | Vaccines: Where Inertia, Innovation, and Revolution Create Value, Simultaneously and Quietly | 277 |
| | <i>Pierre A. Morgon and Hannah Nawi</i> | |
| 13.1 | Introduction | 277 |

| | | |
|-----------|---|------------|
| 13.2 | The World of Vaccines | 278 |
| 13.2.1 | What Are Vaccines? | 278 |
| 13.2.2 | Current Vaccines Are Mainly Prophylactic: Curative Vaccines Are Emerging | 278 |
| 13.2.3 | Drivers to Immunize: Individual and Collective | 280 |
| 13.2.4 | The Pivotal Role of Recommendations | 280 |
| 13.3 | The Vaccine Market: Substantial, Fast Growing, with Intense and Concentrated Competition | 281 |
| 13.4 | The Vaccine Industry: Domination of the Heavyweights, for Now... | 282 |
| 13.4.1 | Barriers to Entry: From R&D Risk to Capital Intensiveness | 290 |
| 13.4.2 | Five Forces Analysis: Competitive Intensiveness and Downstream Hurdles | 291 |
| 13.4.2.1 | Acceptability | 291 |
| 13.4.2.2 | Accessibility | 292 |
| 13.4.2.3 | Availability | 293 |
| 13.4.2.4 | Affordability | 293 |
| 13.5 | New Vaccine Developments: Strategic Trends and Why Innovation Is Needed All along the Value Chain | 295 |
| 13.5.1 | Where Is Innovation Needed? R&D | 296 |
| 13.5.2 | Where Is Innovation Needed? Manufacturing and Product Improvement | 301 |
| 13.5.3 | Where Is Innovation Needed? Acceptability | 301 |
| 13.5.4 | Where Is Innovation Needed? Accessibility, Both as a Function of Supply (Availability) and Logistics | 302 |
| 13.5.5 | Affordability and Sustainability | 303 |
| 13.6 | Where Will Innovation Come from? Strategy and Players | 304 |
| 13.6.1 | Take-Home Messages | 305 |
| | References | 306 |
| 14 | The Patient-Centric Pharma Company: Evolution, Reboot, or Revolution? | 309 |
| | <i>Pierre A. Morgon</i> | |
| 14.1 | Introduction | 309 |
| 14.2 | Health, Always... | 310 |
| 14.3 | The Mission of the Healthcare Industry | 310 |
| 14.4 | Megatrends Affecting the Strategic Scorecard of the Healthcare Industry | 312 |
| 14.5 | Focus on the Societal Trends and Their Consequences for the Management of Healthcare Innovation | 314 |
| 14.6 | The DNA of the Healthcare Industry: R&D and the Management of Innovation | 316 |
| 14.7 | Societal Expectations for Personalized Medicine | 318 |
| 14.8 | New Players Contributing to Information Management to Substantiate Value Propositions for Novel Therapies | 319 |

| | | |
|-----------|--|------------|
| 14.9 | The Role of the Key Stakeholders in Shaping a New Regulatory Framework | 323 |
| 14.10 | The Consequences for the Healthcare Industry in Terms of Governance and Capabilities | 325 |
| 14.11 | The Sustainable Path Forward for the Healthcare Industry | 329 |
| 14.11.1 | Take-Home Messages | 331 |
| | References | 332 |
| 15 | The Pharmaceutical Industry is Opening Its R&D Boundaries | 335 |
| | <i>Alexander Schuhmacher and Ulrich A. K. Betz</i> | |
| 15.1 | Introduction | 335 |
| 15.2 | Open Innovation versus Closed Innovation | 336 |
| 15.3 | Business Models in an Open Innovation Framework | 341 |
| 15.4 | Open Innovation Processes | 342 |
| 15.5 | Capabilities and Attitudes Enabling Open Innovation | 344 |
| 15.6 | Open Innovation in the Pharmaceutical Industry | 345 |
| 15.6.1 | The More Traditional Elements of Open Innovation | 345 |
| 15.6.1.1 | Target Scouting | 345 |
| 15.6.1.2 | Research Collaborations | 346 |
| 15.6.1.3 | Drug Licensing | 346 |
| 15.6.1.4 | Outsourcing | 348 |
| 15.6.1.5 | Joint Ventures | 349 |
| 15.6.2 | The Newer Concepts of Open Innovation | 349 |
| 15.6.2.1 | New Frontier Science | 350 |
| 15.6.2.2 | Drug Discovery Alliances | 350 |
| 15.6.2.3 | Private–Public Partnerships | 351 |
| 15.6.2.4 | Innovation Incubator | 351 |
| 15.6.2.5 | Virtual R&D | 352 |
| 15.6.2.6 | Crowdsourcing | 353 |
| 15.6.2.7 | Open Source Innovation | 355 |
| 15.6.2.8 | Innovation Camps | 355 |
| 15.6.2.9 | Fluctuating Open Teams | 356 |
| 15.7 | New Business Models in View of the Potential of Open Innovation | 356 |
| 15.7.1 | General Trends in the Pharmaceutical Industry | 356 |
| 15.8 | Outlook | 358 |
| | References | 359 |
| 16 | Out-Licensing in Pharmaceutical Research and Development | 363 |
| | <i>Oliver Gassmann, Carol A. Krech, Martin A. Bader, and Gerrit Reepmeyer</i> | |
| 16.1 | Introduction | 363 |
| 16.2 | Performance-Based R&D Collaborations on the Rise | 364 |
| 16.3 | The Impact of Collaborations on the Value Chain | 365 |
| 16.4 | Generating Value from Pipeline Assets by Out-Licensing | 367 |
| 16.5 | Pharmaceutical Companies' Resistance toward Out-Licensing | 372 |

| | | |
|-----------|--|------------|
| 16.6 | Managing Out-Licensing at Novartis: A Case Study | 372 |
| 16.6.1 | Out-Licensing as a 10-Step Process | 373 |
| 16.6.2 | Out-Licensing Contract Design | 375 |
| 16.6.3 | Structure of the Out-Licensing Collaboration with Speedel | 375 |
| 16.7 | Future Directions and Trends | 377 |
| | References | 378 |
| 17 | Trends and Innovations in Pharmaceutical R&D Outsourcing | 383 |
| | <i>Antal K. Hajos</i> | |
| 17.1 | Introduction | 383 |
| 17.2 | Drivers to the Use of Outsourcing | 383 |
| 17.2.1 | Overview on the CRO Market | 383 |
| 17.2.2 | Core versus Noncore Activities | 387 |
| 17.3 | Genesis of Outsourcing in the Twentieth Century: From Commodity to Contribution | 388 |
| 17.3.1 | Outsourcing Portfolio and the Move to Full-Service Provision | 388 |
| 17.3.2 | Globalization and the Emerging Market Hype | 389 |
| 17.3.3 | Procurement Takes over the Outsourcing Function | 391 |
| 17.4 | Current and Future Trends in Outsourcing: From Contribution to Innovation | 392 |
| 17.4.1 | How Has Outsourcing Itself Innovated and What Are the Future Trends? | 392 |
| 17.4.2 | How Does and Will Outsourcing Contribute to Innovation? | 394 |
| 17.5 | Discussion and Conclusion | 395 |
| | References | 398 |
| 18 | New Innovation Models in Pharmaceutical R&D | 401 |
| | <i>Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder</i> | |
| 18.1 | Introduction | 401 |
| 18.2 | Some Attempts That Were Recommended in the Past | 402 |
| 18.3 | The Increasing Pipeline Size | 403 |
| 18.4 | The Reduction of R&D Investments | 404 |
| 18.5 | The Opening of the R&D Processes | 407 |
| 18.6 | The Challenge with the Return on Investment | 411 |
| 18.7 | Changing the R&D Processes Is Not Enough | 412 |
| 18.8 | What Is the Best R&D Model? | 413 |
| | References | 414 |
| 19 | The Influence of Leadership Paradigms and Styles on Pharmaceutical Innovation | 416 |
| | <i>Aubyn Howard</i> | |
| 19.1 | Introduction | 417 |
| 19.2 | What Is Your Concept or Model of Good Leadership? | 419 |
| 19.3 | Approaches to Leadership Modeling and Profiling | 420 |
| 19.3.1 | Personality Types | 421 |

| | | |
|-----------|--|------------|
| 19.3.2 | Behavioral Preferences | 421 |
| 19.3.3 | Developmental Stages | 421 |
| 19.3.4 | Competency Frameworks | 421 |
| 19.4 | The Developmental Approach to Leadership Paradigms and Styles | 422 |
| 19.5 | Inner and Outer Leadership | 424 |
| 19.6 | Dynamics of How Leadership Paradigms Evolve | 425 |
| 19.6.1 | Magic–Animistic | 426 |
| 19.6.2 | Impulsive–Egocentric | 427 |
| 19.6.3 | Conformist–Absolutist | 428 |
| 19.6.4 | Achievement–Multiplistic | 429 |
| 19.6.5 | Pluralistic–Relativistic | 430 |
| 19.6.6 | Evolutionary–Systemic | 432 |
| 19.7 | Leadership at Different Levels within Pharma | 433 |
| 19.8 | Optimizing Innovation in Different Organizational Models and Cultures | 437 |
| 19.9 | How Do We Support the Development of Evolutionary Leaders? | 439 |
| 19.10 | What Does It Mean to Operate from the Evolutionary Paradigm? | 440 |
| 19.11 | Leadership and Personal Mastery | 441 |
| 19.12 | Building an Evolutionary Bridge to Release Innovation | 442 |
| 19.13 | Conclusions | 445 |
| | References | 446 |
| 20 | The Role of Modern Portfolio Management in Pharma Innovation | 449 |
| | <i>Joachim M. Greuel and Axel Wiest</i> | |
| 20.1 | Introduction | 449 |
| 20.2 | Challenges in R&D and the Origin of Pharmaceutical Portfolio Management | 450 |
| 20.3 | Goals and Metrics of Portfolio Management | 451 |
| 20.4 | Portfolio Management as Enabler of Innovation | 456 |
| 20.5 | Modern Portfolio Management Integrates In-House R&D, Business Development, and M&A | 457 |
| | References | 458 |
| 21 | Patent Management Throughout the Innovation Life Cycle | 461 |
| | <i>Martin A. Bader and Oliver Gassmann</i> | |
| 21.1 | Introduction | 461 |
| 21.2 | The Changing Role of Patents: From Legal to Strategic | 462 |
| 21.3 | The Patent Life Cycle Management Model | 467 |
| 21.3.1 | Exploration | 468 |
| 21.3.2 | Generation | 469 |
| 21.3.3 | Protection | 469 |

| | | |
|--------|--------------------------------------|------------|
| 21.3.4 | Optimization | 470 |
| 21.3.5 | Decline | 470 |
| 21.4 | Example: Managing IP Rights at Bayer | 471 |
| 21.5 | Concluding Remarks | 472 |
| | References | 473 |
| | Index | 475 |